Form 4 for ALZN Alzamend Neuro, Inc.
Accepted 2021-09-15 00:00:00 ET · period of report 2021-09-13 · accession 0001214659-21-009539 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-15 | 2021-09-13 | ALZN | GUSTAFSON MARK | Dir | M - OptEx | $0.00 | +2,778 | 2,778 | New | $0 |
| D | 2021-09-15 | 2021-09-13 | ALZN | GUSTAFSON MARK | Dir | M - OptEx | $0.00 | -2,778 | 97.2K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-13 | M | A | 2,778 | $0.00 | 2,778 | D | — | — | |
| 2 | Derivative | Restricted Stock Grant | 2021-09-13 | M | D | 2,778 | $0.00 | 97,222 | D | — · — to 2024-09-13 | 2,778 Common Stock | (F2) Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. (F3) The restricted stock grant vests in 36 equal monthly installments commencing on September 13, 2021. |